PPA
CGEM icon

Parametric Portfolio Associates’s Cullinan Oncology CGEM Stock Holding History

Parametric Portfolio Associates’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$685K Buy
+65,443
New +$884K ﹤0.01% 2948

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
AIG
American International Group New York $2.93M AUM 12.08% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Parametric Portfolio Associates's CGEM Position: Q1 2022 in Review

Parametric Portfolio Associates opened a new position in Cullinan Oncology (CGEM) in Q1 2022: 65,443 shares worth $685K. The stake represents ﹤0.01% of the portfolio and ranks #2948 among its holdings.

82 funds tracked by Wall St. Rank hold CGEM as of Q1 2022.

  • Parametric Portfolio Associates held 65,443 shares of Cullinan Oncology worth $685K as of Q1 2022.
  • Cullinan Oncology was a new Parametric Portfolio Associates position in Q1 2022.
  • Cullinan Oncology made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2948 holding.
  • 82 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.